Solventum Corporation $SOLV Shares Sold by Swedbank AB

Swedbank AB reduced its position in Solventum Corporation (NYSE:SOLV) by 61.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,644 shares of the company’s stock after selling 72,852 shares during the period. Swedbank AB’s holdings in Solventum were worth $3,462,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Ameriprise Financial Inc. grew its position in Solventum by 14.8% during the fourth quarter. Ameriprise Financial Inc. now owns 75,874 shares of the company’s stock valued at $5,023,000 after purchasing an additional 9,776 shares in the last quarter. Royal Bank of Canada grew its position in Solventum by 31.6% during the fourth quarter. Royal Bank of Canada now owns 319,423 shares of the company’s stock valued at $21,101,000 after purchasing an additional 76,757 shares in the last quarter. State of Wyoming purchased a new position in Solventum during the fourth quarter valued at approximately $186,000. Woodline Partners LP purchased a new position in Solventum during the fourth quarter valued at approximately $548,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Solventum by 5.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,106,194 shares of the company’s stock valued at $73,075,000 after purchasing an additional 52,423 shares in the last quarter.

Solventum Stock Performance

Shares of NYSE:SOLV opened at $73.77 on Monday. The company has a market capitalization of $12.79 billion, a price-to-earnings ratio of 34.15, a P/E/G ratio of 3.00 and a beta of 0.53. The firm’s 50 day simple moving average is $72.98 and its 200 day simple moving average is $72.35. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. Solventum Corporation has a fifty-two week low of $60.70 and a fifty-two week high of $85.92.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.12 billion. During the same period last year, the business earned $1.56 EPS. The business’s quarterly revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, sell-side analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Analyst Ratings Changes

SOLV has been the subject of a number of analyst reports. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $80.00 to $103.00 in a research note on Tuesday, July 15th. Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective for the company in a research note on Tuesday, July 1st. Jefferies Financial Group initiated coverage on shares of Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 price objective for the company. Finally, Piper Sandler restated an “overweight” rating and issued a $94.00 price objective (up from $87.00) on shares of Solventum in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $85.44.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.